Dustri Online Services

Search Results

Books: 0	Journals: 1	Articles: 1

Bioavailability Section

Pharmacokinetic comparison of two formulations of talniflumate 370 mg tablets in healthy Korean volunteers 

Yun Kim, Sung- Yim, Bo-Hyung Kim, SeungHwan Lee

Price
42.00 $

Add to Cart

Price

42.00 $

Volume 55 (2017) p. 102 - 108

Abstract

International Journal of Clinical Pharmacology and Therapeutics, Vol. 55 – No. 1/2017 (102-108)

Pharmacokinetic comparison of two formulations of talniflumate 370 mg tablets in healthy Korean volunteers 

Yun Kim¹#², Sung- Yim³, Bo-Hyung Kim³#⁴, SeungHwan Lee² 

¹Program in Biomedical Radiation Sciences, Department of Transdisciplinary Studies, Graduate School of Convergence Science and Technology, Seoul National University, Suwon, ²Department of Clinical Pharmacology and Therapeutics, Seoul National University, College of Medicine and Hospital, ³Department of Clinical Pharmacology and Therapeutics, and ⁴East-West Medical Research Institute, Kyung Hee University College of Medicine and Hospital, Seoul, Korea
Background: Talniflumate, a prodrug of niflumic acid, is a potent analgesic and anti-inflammatory drug that has been widely used for the treatment of rheumatoid diseases. Objective: The aim of this study was to compare the pharmacokinetics and to evaluate the bioequivalence of two formulations of talniflumate 370 mg tablets (test formulation: Flumagen^® 370 mg tablet; reference formulation: Somalgen^® 370 mg tablet). Methods: A randomized, open-label, single dose, two-sequence, two-period crossover clinical study was conducted. After oral administration of the study drug in each period, blood samples were collected up to 15 hours post-dose. The plasma concentration of niflumic acid, a metabolite of talniflumate, was determined using HPLC-MS/MS. The pharmacokinetic parameters were estimated by non-compartmental method. Results: The maximum plasma concentration (C_max) and area under the concentration-time curve from zero to the time point with the last measurable concentration (AUC_last) for the test formulation were 290.7 ± 199 µg/L and 1,154 ± 643 µg×h/L, respectively, and the corresponding values for the reference formulation were 286.8 ± 193 µg/L and 1,151 ± 577 µg×h/L, respectively. The geometric mean ratio and 90% confidence intervals (CI) of the test formulation to the reference formulation for the C_max and AUC_last were 0.983 (0.829 – 1.166) and 0.979 (0.856 – 1.121), respectively. Conclusions: The pharmacokinetic profiles of the test and reference formulations were found not to be significantly different, meeting the Korean regulatory criteria for bioequivalence. Correspondence to:
SeungHwan Lee, MD, PhD
Department of Clinical Pharmacology and Therapeutics
Seoul National University
College of Medicine and Hospital
Daehak-ro, Jongno-gu, Seoul, 03080, Korea 
Email: [email protected]

Shopping Overview

Shopping Overview
Type	Qtty	Discount	VAT	Price
Your basket is empty

View Cart

Search Results

Shopping Overview

Send us an E-Mail